The results of the current investigation are based on the initial 12-week, open-label acute treatment phase of a randomized withdrawal study of duloxetine in the prevention of relapse of MDD. Results ...

INDIANAPOLIS -- Eli Lilly and Co. said yesterday that it received Food and Drug Administration approval to expand the use of its fastest-growing drug, the antidepressant Cymbalta. Regulators approved ...